The Dementia Consortium provides funding, expertise and resources for promising dementia research.
The Dementia Consortium is a private-charity partnership between Alzheimer’s Research UK, Evotec and the pharmaceutical companies Abbvie, Astex Pharmaceuticals, Eisai, Johnson & Johnson, Lilly and MSD. Through the commercial partners, promising projects can be progressed towards the clinic, and revenues shared with the originating scientists. The Consortium provides drug discovery resources, project management, industry expertise and tools as well as full funding support for projects. It can support small molecule or antibody-based strategies and aims to generate tools to achieve preclinical target validation. The ultimate goal is to progress successful projects from laboratories towards the clinic.
The Dementia Consortium funds research into collaborative drug discovery for novel targets and treatments for dementia including Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia and neurodegeneration-associated cognitive defects, plus Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease.
Applications to collaborate with the Dementia Consortium are open globally to academic researchers and SMEs. Previous experience in drug discovery is not required, nor do you need to have any in-house capability for carrying out drug development. The Consortium, through Evotec, is able to provide all of the assay development, screening and medicinal chemistry resources required to develop novel compounds or antibodies against the target.
To apply, visit the Dementia Consortium website.
For promising data that are too preliminary to progress with our Dementia Consortium, our Target Validation Pathfinder Grant offers up to £50,000 to support translational research that shows potential for collaboration.